Panbela Therapeutics Q1 2024 GAAP EPS $(2.28) Misses $(1.48) Estimate
Portfolio Pulse from Benzinga Newsdesk
Panbela Therapeutics (NASDAQ:PBLA) reported a Q1 2024 GAAP EPS of $(2.28), significantly missing the analyst consensus estimate of $(1.48) by 54.05%.
May 15, 2024 | 8:21 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Panbela Therapeutics reported a Q1 2024 GAAP EPS of $(2.28), missing the analyst consensus estimate of $(1.48) by 54.05%. This significant miss is likely to negatively impact the stock price in the short term.
The significant miss on earnings per share (EPS) compared to analyst expectations is likely to result in a negative market reaction. Investors typically view such a large miss as a sign of underlying issues, leading to a potential sell-off.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100